opinion piece caught eye new england journal medicine week number reasons first involves least favorite antidepressant i always interested may broadened indications i stopped prescribing paroxetine well years ago i considered unfavorable pharmacokinetic side effect profile case potential interaction could decrease efficacy tamoxifen medication used treat breast cancer capacity consultant i frequently encounter people already paroxetine continue preference i encounter people side effects either transition medication onto something else depending clinical scenario second fda decision making always interesting follow also true case like recent zohydro decision fda decided go recommendation scientific committee approve specified name brand product hot flashes third remarketing generics brand name drugs slightly different formulations another interesting aspect fda regulation case also true product case brisdelle mg tablet paroxetine paroxetine currently available generic drug mg immediate release tablets mg controlled release preparations mg tablets scored allowing approximation approved product another interesting pint action apparently year old according fda release scientific evidence comes two randomized double blind placebo controlled trials women baseline moderate severe hot flashes occurring rate per day effects observed trial described modest overall decrease hot flashes per day week one study per day despite slight effect women active drug reported meaningful difference end study months balancing risk rewards study regulatory decision fda reproductive health drugs advisory committee voted approving brisdelle authors speculate modest efficacy existing warnings suicidality swayed advisory committee vote i thought interesting authors consider safety profile paroxetine well established paroxetine seems one complained medications internet favorite critics consider watchdogs pharmaceutical industry case brisdelle formulation side effects exceed placebo anyone used prescribing selective serotonin reuptake inhibitor ssri type antidepressants aware possible significant discontinuation syndrome authors suggest brisdelle need tapered discontinued package insert web site suggests potential problems including potential discontinuation symptoms symptoms neonates exposed medication authors discuss importance non hormonal agent treat hot flashes especially give impact lifestyle risks stroke coronary artery disease thromboembolism breast cancer current fda approved treatment hormonal therapy form estrogen estrogen progestin problem using ssris snris hot flashes already fairly widespread practice backed degree double blind controlled trials approval fda goal study i medline search controlled clinical trials hot flashes came rough collection look specific studies find positive negative i look meta analyses interesting opinion naturally one matched mine i found study study authors correctly conclude potent cypd inhibitors avoided women taking tamoxifen recommendation avoid paroxetine ignored using database netherlands paroxetine remains widely prescribed antidepressant last reference reflects opinion paroxetine general certainly specific problem also example fda could consciously avoid problems rather sending free market waiting post marketing surveillance acceptable case serious conditions current therapies case alternate therapies scientific backing readily available experts field recommending use paroxetine i also concern impact remarketing generic drug unusual dose generic drug market general i thinking precedent generic doxepin remarketed silenor unique dosages mg pharmacies generic doxepin mg tablets smallest available dose size liquid form ordered additional dose adjustments impression prescribing doxepin low doses increased general recognition low doses used insomnia doxepin primarily substrate cyp enzymes point could probably accumulate higher doses thing happens paroxetine may result standard antidepressant doses prescribed hot flashes could lead complications potentially drug interactions george dawson md dfapa ronald orleans li li ph myong jin kim pharm jia guo ph mahboob sobhan ph lisa soule hylton v joffe sc fda approval paroxetine menopausal hot flashes engl med binkhorst l mathijssen rh van herk sukel mp bannink jager wiemer ea van gelder unjustified prescribing cypd inhibiting ssris women treated tamoxifen breast cancer res treat jun doi z epub jun pubmed pmid